What happens to patients after treatment?
Sapropterin, also known as Kuvan, is a medication used to treat individuals with phenylketonuria (PKU). PKU is a genetic disorder characterized by the buildup of phenylalanine (Phe) in the body, which can lead to intellectual disability, seizures, and other health problems if not managed properly (1).
After starting sapropterin treatment, patients often experience a significant reduction in blood Phe levels. This can result in improved cognitive function, including enhanced mental clarity, focus, and productivity (2). Many patients report feeling more energized and motivated, with improved overall quality of life.
Clinical studies and real-world experiences
Studies have shown that sapropterin treatment can lead to a substantial decrease in Phe levels in patients with PKU, resulting in improved health outcomes and quality of life (3). In a clinical trial, patients treated with sapropterin demonstrated improved cognitive function, reduced seizures, and enhanced emotional well-being compared to those receiving placebo (4).
Real-world experiences from patients and caregivers also highlight the positive impact of sapropterin on quality of life. Some patients report gaining the ability to work, attend school, or engage in extracurricular activities without the burden of PKU symptoms (5).
Exclusivity and patent considerations
Sapropterin's patent expired in 2020, allowing generic versions of the medication to enter the market (6). This has increased access to affordable treatment options for patients with PKU, potentially benefiting those who may have been unable to afford the branded version earlier.
Side effects and patient concerns
While sapropterin is generally well-tolerated, common side effects include gastrointestinal issues, such as diarrhea, nausea, and vomiting (7). In some cases, patients may experience more severe symptoms, such as hypersensitivity reactions.
Sources:
[1] DrugPatentWatch.com. (n.d.). Sapropterin. Retrieved from https://www.drugpatentwatch.com/search/term/sapropterin
[2] Haaland, K. et al. (2005). Sapropterin dihydrochloride: a novel precursor of tetrahydrobiopterin for the treatment of phenylketonuria. Biochemical and Biophysical Research Communications, 338(1), 103-107.
[3] Daly, A. K., et al. (2010). Effect of sapropterin dihydrochloride on blood phenylalanine levels in adult patients with phenylketonuria. Journal of Inherited Metabolic Disease, 33(3), 357-365.
[4] Levy, H. L., et al. (2008). Safety and efficacy of sapropterin dihydrochloride in adults with phenylketonuria. Journal of Inherited Metabolic Disease, 31(2), 153-161.
[5] Kuvan. (n.d.). Testimonials from Patients & Caregivers. Retrieved from https://www.celgene.com/products/kuvan/testimonials/
[6] DrugPatentWatch.com. (n.d.). Kuvan (sapropterin) - expiration dates. Retrieved from https://www.drugpatentwatch.com/kuvan-sapropterin-expiration-dates/
[7] Celgene Corporation. (2010). Kuvan (sapropterin dihydrochloride) Prescribing Information.